Hot Article Directory San Andrés y Providencia

Sunday, March 13, 2011

Vesanoïd

Vesanoïd may be available in the countries listed below.

Ingredient matches for Vesanoïd

Tretinoin

Tretinoin is reported as an ingredient of Vesanoïd in the following countries:

France

International Drug Name Search

In the US, Propafenone (propafenone systemic) is a member of the drug class group I antiarrhythmics and is used to treat Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia and Wolff-Parkinson-White Syndrome.

US matches:

Propafenone

Propafenone Sustained-Release Capsules

Propafenone Hydrochloride

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C01BC03

CAS registry number (Chemical Abstracts Service)

0054063-53-5

Chemical Formula

C21-H27-N-O3

Molecular Weight

341

Therapeutic Category

Antiarrhythmic agent

Chemical Name

1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-

Foreign Names

Propafenonum (Latin)
Propafenon (German)
Propafénone (French)
Propafenona (Spanish)

Generic Names

Propafenone (OS: BAN, DCIT)
Propafénone (OS: DCF)
Propafenone Hydrochloride (OS: BANM, USAN, JAN)
Fenopraine hydrochloride (IS)
SA 79 (IS)
WZ 88462-3 (IS)
Propafenone Hydrochloride (PH: BP 2010, Ph. Eur. 6, USP 32)
Propafenoni hydrochloridum (PH: Ph. Eur. 6)

Brand Names

Polfenon
Polpharma, Poland

Propafenon Hexal
Hexal, Luxembourg

Propafenonã
Arena, Romania

Propafenon-Hexal
Hexal, Luxembourg

Rytmonorm
Abbott, Germany

Apo-Propafenone
Apotex, Canada

Arythmol
Abbott, United Kingdom; Abbott, Ireland

Cardiofenone
Polifarma, Italy

Cuxafenon
TAD, Germany

Fenorit
Scharper, Italy

Gen-Propafenone
Genpharm, Canada

Nistaken
Kendrick, Mexico

Normorytmin
Abbott, Argentina

Profenan
Slaviamed, Serbia

Profex
Taro, Israel

Prolekofen
Lek, Czech Republic; Sandoz, Slovakia

Pronon
Astellas, Japan

Propafen
Heimdall, Colombia; Zorka, Serbia

Propafenon AL
Aliud, Czech Republic; Aliud, Germany; Aliud, Hungary; Aliud, Romania

Propafenon Alkaloid
Alkaloid, Croatia (Hrvatska)

Propafenon Genericon
Genericon, Croatia (Hrvatska)

Propafenon HCl PCH
Pharmachemie, Netherlands

Propafenon Heumann
Heumann, Germany

Propafenon Hexal
Hexal, Germany

Propafenon Pharmavit
Walmark, Hungary

Propafenon Sandoz
Sandoz, Germany

Propafenon Siga
Sigapharm, Germany

Propafenon Stada
Stada, Germany

Propafenon
Alkaloid, Serbia; Alkaloid, Slovenia; Genericon, Austria

Propafenon-CT
CT Arzneimittel, Germany

Propafenone Alter
Alter, Italy

Propafenone DOC
DOC Generici, Italy

Propafenone Hydrochloride
Ethex, United States; KV Pharmaceutical, United States; Mutual, United States; Pliva, United States; Qualitest, United States; United Research, United States; URL, United States; Vintage, United States; Watson, United States

Propafenone Pensa
Pensa, Italy

Propafenone ratiopharm
Ratiopharm, Italy

Propafenone Sandoz
Sandoz, Italy

Propafenon-ratiopharm
Ratiopharm, Germany

Propanorm
Pro.Med.CS, Bosnia & Herzegowina; Pro.Med.CS, Czech Republic; Pro.Med.CS, Estonia; Pro.Med.CS, Georgia; Pro.Med.CS, Lithuania; Pro.Med.CS, Russian Federation; Pro.Med.CS, Slovakia

Ritmocor
Drugtech-Recalcine, Chile

Ritmonorm
Knoll, Brazil

Ropaful
Choseido Pharmaceutical, Japan

Rythmex
Teva, Israel

Rythmol
Abbott, Canada; Abbott, France; Abbott, South Africa; GlaxoSmithKline, United States

Rytmocard
Abbott, Philippines; Sopharma, Bulgaria

Rytmonorm
Abbott, Bosnia & Herzegowina; Abbott, Belgium; Abbott, Bulgaria; Abbott, Switzerland; Abbott, China; Abbott, Colombia; Abbott, Costa Rica; Abbott, Czech Republic; Abbott, Germany; Abbott, Denmark; Abbott, Estonia; Abbott, Spain; Abbott, Finland; Abbott, Georgia; Abbott, Guatemala; Abbott, Hong Kong; Abbott, Honduras; Abbott, Croatia (Hrvatska); Abbott, Hungary; Abbott, Indonesia; Abbott, Iceland; Abbott, Italy; Abbott, Lithuania; Abbott, Luxembourg; Abbott, Latvia; Abbott, Nicaragua; Abbott, Netherlands; Abbott, New Zealand; Abbott, Panama; Abbott, Peru; Abbott, Poland; Abbott, Portugal; Abbott, Romania; Abbott, Russian Federation; Abbott, Sweden; Abbott, Singapore; Abbott, Slovenia; Abbott, Slovakia; Abbott, El Salvador; Abbott, Thailand; Abbott, Turkey; Abbott, Taiwan; Abbott, Venezuela; Ebewe, Bulgaria; Ebewe, Romania; Knoll, United Arab Emirates; Knoll, Bahrain; Knoll, Egypt; Knoll, Iran; Knoll, Jordan; Knoll, Kuwait; Knoll, Lebanon; Knoll, Qatar; Knoll, Saudi Arabia

Rytmonorma
Abbott, Austria

Rytmo-Puren
Actavis, Germany

Sobiral
Ohara Yakuhin, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Saturday, March 12, 2011

Leucodar

Leucodar may be available in the countries listed below.

Ingredient matches for Leucodar

Fluconazole

Fluconazole is reported as an ingredient of Leucodar in the following countries:

Bangladesh

International Drug Name Search

Friday, March 11, 2011

Tyvaso

Tyvaso is a brand name of treprostinil, approved by the FDA in the following formulation(s):

TYVASO (treprostinil sodium - solution; inhalation)

Manufacturer: UNITED THERAP

Approval date: July 30, 2009

Strength(s): EQ 0.6MG BASE/ML ^[RLD]

Has a generic version of Tyvaso been approved?

No. There is currently no therapeutically equivalent version of Tyvaso available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of treating pulmonary hypertension with benzidine prostaglandins
Patent 5,153,222
Issued: October 6, 1992
Inventor(s): Tadepalli; Anjaneyulu S. & Long; Walker A. & Crow; James W. & Klein; Kenneth B.
Assignee(s): Burroughs Wellcome Co.
The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Patent expiration dates:
- October 16, 2014
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION

Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
Patent 6,521,212
Issued: February 18, 2003
Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
Assignee(s): United Therapeutics Corporation
A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Patent expiration dates:
- November 13, 2018
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

Method for delivering benzindene prostaglandins by inhalation
Patent 6,756,033
Issued: June 29, 2004
Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
Assignee(s): United Therapeutics Corporation
A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Patent expiration dates:
- November 13, 2018
  ✓
  Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

Process for stereoselective synthesis of prostacyclin derivatives
Patent 6,765,117
Issued: July 20, 2004
Inventor(s): Robert M.; Moriarty & Raju; Penmasta & Liang; Guo & Munagala S.; Rao & James P.; Staszewski
Assignee(s): United Therapeutic Corporation
An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF1-type compounds.
Patent expiration dates:
- October 24, 2017
  ✓
  Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- July 30, 2012 - NEW DOSAGE FORM
- July 30, 2016 - ORPHAN DRUG EXCLUSIVITY

Monday, March 7, 2011

Cisplatine Mayne

Cisplatine Mayne may be available in the countries listed below.

Ingredient matches for Cisplatine Mayne

Cisplatin

Cisplatin is reported as an ingredient of Cisplatine Mayne in the following countries:

Luxembourg

International Drug Name Search

Sunday, March 6, 2011

Nongonococcal Urethritis Medications

Definition of Nongonococcal Urethritis: Urethritis not resulting from gonococcal infection. Venereally transmitted Chlamydia trachomatis is the most common cause.

Drugs associated with Nongonococcal Urethritis

The following drugs and medications are in some way related to, or used in the treatment of Nongonococcal Urethritis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.